VBI Vaccines Announces Poster Presentation at EASL 2023
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.
- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting T-cell responses and durability of immune responses following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine, PreHevbrio™ [Hepatitis B Vaccine (Recombinant)], has been accepted for poster presentation at The International Liver Congress™ 2023 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 21-24.
- Title: T-cell responses to Pre-S1 and Pre-S2 are correlated to anti-HBs antibody titers, which are higher and persist longer in volunteers vaccinated with 3-antigen than with 1-antigen hepatitis B vaccine in the PROTECT Study: 3.5 year follow up
Session: Poster – Viral hepatitis B and D: Clinical aspects
Presenter: Andrew Boyle, Medical Science Liaison (MSL) U.K., employed at Syneos Health on behalf of VBI
Following the conference, the poster will be archived on the Posters page in the News & Resources section of VBI’s website, here .